Michael Maxwell is a Special Counsel and senior scientific analyst, with more than a decade's experience in product liability and toxic tort litigation, as well as in the provision of ongoing regulatory, insurance, health, safety and environmental issues advice.

Michael’s legal skills are complemented by his scientific research background in Pharmacology and Toxicology, with a PhD in Pharmacology.

Read More

Expertise

Expand all

Environmental and Toxic Tort Litigation

Michael has acted in a wide range of complex litigious and advisory matters on behalf of companies from the mining, pharmaceutical, transport, motor vehicle and chemicals industries. These matters typically required sophisticated analysis of emerging theories of liability and cutting-edge toxicological and industrial hygiene issues, including close collaboration with leading international experts. For example:

  • Speculative low-level exposure claims: Defence of test case litigation and advice to major corporations, including multinationals, on true health and litigious risks arising from low-level exposures to a vast range of chemicals. Claims by individuals, or groups of individuals, have been for a range of speculative (eg. MCS) and complex multifactorial diseases (cancer and respiratory illness).

See Environmental and Toxic Tort Litigation

Litigation and Dispute Resolution

Michael has acted in a wide range of complex litigious and advisory matters on behalf of companies from the mining, pharmaceutical, transport, motor vehicle and chemicals industries. These matters typically required sophisticated analysis of emerging theories of liability and cutting-edge toxicological and industrial hygiene issues, including close collaboration with leading international experts. For example:

  • Speculative low-level exposure claims: Defence of test case litigation and advice to major corporations, including multinationals, on true health and litigious risks arising from low-level exposures to a vast range of chemicals. Claims by individuals, or groups of individuals, have been for a range of speculative (eg. MCS) and complex multifactorial diseases (cancer and respiratory illness).
  • Pharmaceuticals: Risk management advice and defence of claims, including class actions, involving comprehensive and complex expert input, particularly concerning alleged side effects. Key issues typically include the robustness and validity of evidence on side effects from clinical trials and various forms of mechanistic, epidemiological and statistical evidence.
    Michael has particular experience in the preparation of expert evidence to address issues such as drug side-effects, complex or contentious epidemiological and clinical trial evidence, brain chemistry and injury, psychoactive compounds, addiction and alleged low-level exposure to a range of malodorous and potentially harmful compounds (particularly respiratory irritants, radiation and possible carcinogens).

See Litigation and Dispute Resolution

Class Actions

Michael has acted in a wide range of complex litigious and advisory matters on behalf of companies from the mining, pharmaceutical, transport, motor vehicle and chemicals industries. These matters typically required sophisticated analysis of emerging theories of liability and cutting-edge toxicological and industrial hygiene issues, including close collaboration with leading international experts. For example:

  • Speculative low-level exposure claims: Defence of test case litigation and advice to major corporations, including multinationals, on true health and litigious risks arising from low-level exposures to a vast range of chemicals. Claims by individuals, or groups of individuals, have been for a range of speculative (eg. MCS) and complex multifactorial diseases (cancer and respiratory illness).
  • Pharmaceuticals: Risk management advice and defence of claims, including class actions, involving comprehensive and complex expert input, particularly concerning alleged side effects. Key issues typically include the robustness and validity of evidence on side effects from clinical trials and various forms of mechanistic, epidemiological and statistical evidence.

See Class Actions

Product Liability

Michael has acted in a wide range of complex litigious and advisory matters on behalf of companies from the mining, pharmaceutical, transport, motor vehicle and chemicals industries. These matters typically required sophisticated analysis of emerging theories of liability and cutting-edge toxicological and industrial hygiene issues, including close collaboration with leading international experts. For example:

  • Pharmaceuticals: Risk management advice and defence of claims, including class actions, involving comprehensive and complex expert input, particularly concerning alleged side effects. Key issues typically include the robustness and validity of evidence on side effects from clinical trials and various forms of mechanistic, epidemiological and statistical evidence.

See Product Liability

Knowledge

    Related knowledge information is loading